Last Update 04 Jun 26

LXRX: Higher Future P/E And Novo Partnership Milestones Will Drive Repricing

Narrative Update: Lexicon Pharmaceuticals Analyst Price Target Shift

Analysts have raised their price target on Lexicon Pharmaceuticals to $2.30 from $2.10. The change reflects updated views on the company that incorporate a slightly lower assumed profit margin and a higher future P/E multiple in the latest model.

Analyst Commentary

Recent research commentary around Lexicon Pharmaceuticals focuses on how updated assumptions feed into the raised US$2.30 price target, particularly around profitability expectations and the P/E multiple used in models.

Bullish Takeaways

Bullish analysts point to the higher P/E multiple in their models as a sign that they see room for the stock to support a richer valuation based on their expectations for the business.
The higher US$2.30 target, compared with the prior US$2.10 level, signals greater confidence in the company’s longer term potential even with more conservative profit margin assumptions.
By lifting the target while tempering margin expectations, bullish analysts suggest that they see execution on growth initiatives as more important to the equity story than near term profitability.
The reaffirmed positive stance on the stock implies that, in their view, the current share price does not yet fully reflect the outcomes they model for revenue scale and earnings power.

Bearish Takeaways

The use of a lower assumed profit margin in the updated model highlights that some analysts see risk around how quickly the company can reach higher levels of profitability.
A higher P/E multiple also means the valuation relies more heavily on future execution, which can leave the stock exposed if the company’s progress does not line up with analysts’ expectations.
The relatively modest absolute change in the price target suggests that, while the view remains constructive, some caution is embedded around how much upside is achievable from current levels.
Investors may want to keep in mind that any delay in improving margins or reaching scale could lead bearish analysts to question the level of optimism implied by the raised target and higher multiple.

What's in the News

Lexicon stockholders approved the Seventh Amended and Restated Certificate of Incorporation at the April 30, 2026 annual meeting, which had been proposed to increase authorized common shares from 450,000,000 to 900,000,000. Source: Company bylaws filing
Lexicon and Novo Nordisk reported that Novo Nordisk has started a Phase 1 trial of LX9851, an oral, non incretin candidate for obesity and related metabolic disorders. Under the agreement, Lexicon received a second US$10 million milestone payment and is eligible for a third US$10 million milestone in 2026. Source: Product announcement
The LX9851 license agreement with Novo Nordisk provides for up to US$1b in upfront and potential development, regulatory and sales milestones, plus tiered royalties on future net sales. These economics are tied to Novo Nordisk’s worldwide rights to develop, manufacture and commercialize the drug. Source: Product announcement
New post hoc clinical data on sotagliflozin in type 1 diabetes, using pooled 52 week trial results across kidney function subgroups, are being presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes. Reported effects include changes in HbA1c, body weight, systolic blood pressure, insulin use and hypoglycemia. Source: Product announcement
Lexicon plans to resubmit the New Drug Application for ZYNQUISTA (sotagliflozin) for glycemic control in type 1 diabetes in 2026, following U.S. FDA feedback and additional data from the STENO1 study conducted by the Steno Diabetes Center in Denmark. Source: Product announcement

Valuation Changes

Fair Value: Modelled fair value remains at $3.72, with no change between the prior and updated assumptions.
Discount Rate: The discount rate is effectively unchanged at 7.108%, indicating a consistent required return in the model.
Revenue Growth: The assumed long term revenue growth rate is stable at about 5.55%, with only an immaterial adjustment in the updated figures.
Net Profit Margin: Net profit margin has been trimmed from 20.44% to 19.56%, a modest reduction that lowers the profitability assumption in the model.
Future P/E: The future P/E multiple has risen from 133.80x to 155.25x, a sizable increase that places more weight on higher valuation levels in the outer year assumptions.

6 views

Key Takeaways

Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.
Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.
Strategic partnerships and increased R&D investments introduce dependency risks and elevate costs, affecting Lexicon's financial stability, revenue potential, and market opportunities.

Catalysts

About Lexicon Pharmaceuticals

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.What are the underlying business or industry changes driving this perspective?

Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non-opioid treatment for diabetic peripheral neuropathic pain in over two decades, which could significantly impact future revenue growth and market share.
The company is developing LX9851, a first-in-class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data, which could open new revenue streams and target high-demand markets once the IND is submitted in 2025.
The strategic licensing agreement with Viatris for sotagliflozin outside the U.S. and Europe provides a financial catalyst by reducing operational burden while ensuring revenue through licensing fees and potential royalties.
Sotagliflozin's ongoing pivotal Phase III SONATA-HCM study could lead to expanded label indications for hypertrophic cardiomyopathy, potentially increasing market penetration and future earnings if approved.
Cost reduction initiatives, such as ceasing INPEFA promotion and employee restructuring, anticipate reduced operating expenses going forward, improving net margins and potentially enhancing future profitability.

Lexicon Pharmaceuticals Earnings and Revenue Growth

Lexicon Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Lexicon Pharmaceuticals's revenue will grow by 5.5% annually over the next 3 years.
Analysts are not forecasting that Lexicon Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Lexicon Pharmaceuticals's profit margin will increase from -37.5% to the average US Pharmaceuticals industry of 19.6% in 3 years.
If Lexicon Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $16.0 million (and earnings per share of $0.03) by about June 2029, up from -$26.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $24.5 million in earnings, and the most bearish expecting $-131.0 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 155.3x on those 2029 earnings, up from -31.5x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 15.0x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Lexicon Pharmaceuticals relies on strategic repositioning and partnerships to advance its clinical programs, which introduces dependency risks and potential delays, potentially affecting future revenues and market opportunities.
The company ceased promotional efforts for INPEFA in the U.S. due to a difficult market access environment, reflecting challenges in generating significant revenue from this asset and indicating competitive pressures that may affect earnings.
There was an increase in R&D expenses due to investments in clinical trials, leading to elevated operating costs which could impact net margins, especially if these programs do not yield successful outcomes or commercial products.
Lexicon reported a net loss for 2024, which, despite revenue from a new licensing agreement, highlights financial challenges and the risk of not achieving profitability, impacting overall financial stability and sustainability.
The ongoing need for additional pivotal trials and regulatory approvals for its pipeline suggests potential high costs and risks in drug development, which could strain financial resources and impact future earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $3.72 for Lexicon Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $1.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $81.9 million, earnings will come to $16.0 million, and it would be trading on a PE ratio of 155.3x, assuming you use a discount rate of 7.1%.
Given the current share price of $1.85, the analyst price target of $3.72 is 50.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Lexicon Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options